Related Experiment Video

Updated: Jun 19, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Outcome after device implantation in chronic heart failure is dependent on concomitant medical treatment

Christopher Adlbrecht1, C Adlbrecht, M Hülsmann

  • 1Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.

European Journal of Clinical Investigation
|October 22, 2009
PubMed

Insights

Optimizing medical therapy in chronic heart failure patients receiving cardiac resynchronization therapy (CRT) improves outcomes. Non-optimized pharmacotherapy significantly increases the risk of death or hospitalization.

Area of Science:

  • Cardiology
  • Medical Device Therapy
  • Pharmacotherapy

Background:

  • Cardiac resynchronization therapy (CRT) with or without implantable cardioverter/defibrillator (ICD) is established for symptomatic chronic heart failure (CHF).
  • Optimization of medical therapy in CHF patients undergoing device implantation is recommended but its impact remains understudied.
  • Real-world data suggests medical therapy is often not titrated to optimal dosages in CHF patients.

Purpose of the Study:

  • To evaluate the real-life impact of CRT versus CRT/ICD on patient outcomes.
  • To assess the influence of pharmacotherapy optimization on outcomes in CHF patients with device therapy.

Main Methods:

  • Retrospective observational cohort study of 205 CHF patients (95 CRT, 110 CRT/ICD).
  • Comparison of outcomes between patients achieving guideline-recommended pharmacotherapy dosages and those who did not.
  • Mean follow-up of 16.8 months.

Main Results:

  • 41% of patients reached the primary endpoint of all-cause death or cardiac hospitalization.
  • CRT/ICD group had a significantly higher event rate (52.7%) compared to the CRT group (26%).
  • Non-optimized medical therapy (HR=2.080) and CRT/ICD vs. CRT (HR=2.504) were significant predictors of the primary endpoint.

Conclusions:

  • Professional monitoring and titration of pharmacotherapy are crucial for CHF patients, including those receiving device therapy.
  • Optimizing medical therapy alongside device implantation can improve outcomes in chronic heart failure.
  • Specialized heart failure units or cardiologists should oversee pharmacotherapy management in device-treated CHF patients.
Abstract

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...